
Lexeo Therapeutics has announced a strategic partnership with life sciences investors Perceptive Xontogeny Venture Funds (PXV Funds) and venBio Partners …
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader

